Integrated DNA Technologies Introduces New HIV Panel to Advance Virology Research
xGen™ HIV Amplicon Panel provides a single-tube, 2.5-hour workflow
designed to enable detection down to 1,000 viral genome copies
CORALVILLE, Iowa (June 24,2024)—Global genomics solutions provider, Integrated DNA Technologies (IDT), is bringing a new solution to address challenges researchers face in accelerating Human Immunodeficiency Virus (HIV) drug discovery and research. The company announced availability of the xGen HIV Amplicon Panel consisting of primers designed to cover 99.3% of the HIV genome. Powered by IDT’s xGen Amplicon Technology, the HIV panel provides a single-tube, two-step PCR amplification workflow that uses overlapping primer sets to obtain high levels of genome coverage from as low as 1,000 double-stranded viral genome copies.
“This launch represents one of the many ways IDT is continuing to innovate on its NGS portfolio, comprised of stand-alone library preparation, target enrichment, and normalization chemistries, as well as connected NGS solutions, to support researchers exploring viral evolution, epidemiological studies, drug resistance mechanisms and drug development research,” said Steven Henck, PhD, Vice President, R&D at Integrated DNA Technologies. “While the scientific community has learned a lot about HIV and the disease it causes, continued research is needed to help the millions of people whose health continues to be threatened by the global HIV/AIDS pandemic. We believe our xGen HIV Amplicon Panel provides an accessible option for researchers and will be foundational to unlocking future discoveries and advancing HIV research.”
IDT’s xGen HIV Amplicon Panel offers a streamlined workflow that goes from sample to sequencer in 2.5 hours with up to 1536 unique dual indexing primers (UDIs) for multiplexed sequencing. This predesigned xGen Amplicon Panel built with xGen Amplicon Technology includes amplicon tiling and creation of super amplicons to ensure comprehensive genome coverage across existing variant genomes and provide resistance to future viral mutations that may fall within a priming site, thus enabling future identification of novel variants.
To learn more or order IDT’s xGen HIV Amplicon Panel, visit idtdna.com/ngsHIV.
About IDT
Seeking to fulfill its mission of accelerating the pace of genomics, IDT acquired Archer™ NGS Research Assays in December 2022. When combined with its existing solutions, the expanded portfolio helps realize the shared vision of enabling researchers to rapidly move from the lab to life-changing advances.
IDT’s infrastructure supports customers around the globe with its manufacturing headquarters situated in Coralville, Iowa, USA, with additional manufacturing sites in San Diego, California, USA; Boulder, Colorado, USA; Research Triangle Park, North Carolina, USA; Ann Arbor, Michigan, USA; Leuven, Belgium; and Singapore.
IDTis proud to be part of Danaher. Danaher’s science and technology leadership puts IDT’s solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers.
Together with Danaher’s other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day.
For more information about IDT, visit www.idtdna.comand follow the company on LinkedIn, X, Facebook, YouTube, and Instagram.
Disclaimer: RUO — For research use only. Not for use in diagnostic procedures. Unless otherwise agreed to in writing, IDT does not intend these products to be used in clinical applications and does not warrant their fitness or suitability for any clinical diagnostic use. RUO24-2923_001